Skip to main content

Table 2 Univariate analysis of clinical pathology and prognosis of 2917 BC patients with bone metastasis

From: Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

Variables

Number

Median survival time (month)

95% confidence interval (CI)

χ2

P-value

Race

     

White

2255

44

41.617–46.383

35.071

 < 0.001

Black

462

31

27.607–34.393

  

Other

200

43

31.973–54.027

  

Grade

     

1

287

46

37.721–54.279

  

2

1440

46

42.998–49.002

45.128

 < 0.001

3–4

1190

34

31.198–37.002

  

Marital

     

Married

1416

48

44.517–51.483

45.771

 < 0.001

Unmarried

1501

36

33.209–38.791

  

Age

     

 ≤ 35

134

56

38.548–73.452

  

35 < age < 60

1345

46

42.387–49.613

70.468

 < 0.001

 ≥ 60

1438

36

33.066–38.934

  

Ethnic origin

     

Spanish-Hispanic-Latino

289

47

41.597–52.403

2.103

0.147

Non-Spanish-Hispanic-Latino

2628

41

38.983–43.017

  

Laterality

     

Left

1525

42

39.446–44.554

0.017

0.896

Right

1392

42

39.085–44.915

  

Histology

     

IDC

2351

44

41.537–46.463

25.295

 < 0.001

Non-IDC

566

36

32.245–39.755

  

T stage

     

T1

383

47

38.824–55.176

  

T2

1158

47

42.855–51.145

53.468

 < 0.001

T3

553

40

35.692–44.308

  

T4

823

34

30.984–37.016

  

N stage

     

N0

704

39

34.668–43.332

  

N1

1326

43

39.941–46.059

5.582

0.134

N2

406

43

37.639–48.361

  

N3

481

42

38.004–45.996

  

Radiation

     

Yes

1302

46

42.593–49.407

14.906

 < 0.001

No

1615

39

36.512–41.488

  

Chemotherapy

     

Yes

1564

48

44.242–51.758

64.579

 < 0.001

No

1353

36

33.254–38.746

  

Subtype

     

ER + /HER2−

2114

43

41.030–44.970

  

ER + /HER2 + 

433

57

48.725–65.275

242.199

 < 0.001

HER2 + 

122

73

0

  

TNBC

248

13

11.349–14.651

  

ER

     

Positive

2532

44

42.077–45.923

91.338

 < 0.001

Negative

385

18

14.319–21.681

  

PR

     

Positive

2121

46

43.765–48.235

97.923

 < 0.001

Negative

796

27

23.973–30.027

  

HER2

     

Positive

555

58

46.618–69.382

30.843

 < 0.001

Negative

2362

40

37.931–42.069

  

Primary surgery

     

Operation

1245

56

51.508–60.492

146.023

 < 0.001

Non-operation

1672

33

30.830–35.170

  

Surgical mode

     

Non-operation

1672

33

30.830–35.170

  

BCS

381

70

0

157.117

 < 0.001

Mastectomy

255

59

45.751–72.249

  

Radical mastectomy

609

48

43.369–52.631

  
  1. ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us